Showing results (1-10 of 73) with videos related to
Sort By:
Pageof 8
Clinical Pharmacology in Drug Development|August 22, 2023
Safety, Pharmacokinetics, and Exposure-Response Modeling of Nedosiran in Participants With Severe Chronic Kidney DiseaseAniruddha Amrite, Ernesto Fuentes, Thomas C Marbury, et al.Blood Pressure Monitoring|May 17, 2006
Use of 24-h ambulatory blood pressure monitoring to assess blood pressure control: a comparison of olmesartan medoxomil and amlodipine besylateSteven G Chrysant, Thomas C Marbury, Tonous N SilfaniVaccine|February 7, 2012
Phase I dose finding studies of an adjuvanted Clostridium difficile toxoid vaccineRichard N Greenberg, Thomas C Marbury, Ginamarie Foglia, et al.American Journal of Therapeutics|January 14, 2014
The effect of renal and hepatic impairment on the pharmacokinetics of ospemifene, a tissue-selective estrogen agonist/antagonistRichard A Preston, Thomas C Marbury, Toshihiro Wajima, et al.Journal of Clinical Pharmacology|December 5, 2002
Pharmacokinetics and safety of a single oral dose of once-daily alfuzosin, 10 mg, in male subjects with mild to severe renal impairmentThomas C Marbury, Robert A Blum, Clémence Rauch, et al.Antimicrobial Agents and Chemotherapy|August 3, 2022
Safety and Pharmacokinetics of Taniborbactam (VNRX-5133) with Cefepime in Subjects with Various Degrees of Renal ImpairmentJames A Dowell, Thomas C Marbury, William B Smith, et al.British Journal of Clinical Pharmacology|November 22, 2024
The pharmacokinetics of brensocatib in participants with renal impairment following a single oral administrationSam Au Yeung, Daniel S Stein, Thomas C Marbury, et al.Journal of Clinical Pharmacology|April 19, 2024
Effect of Hepatic Impairment on Trilaciclib PharmacokineticsChao Li, Richard A Preston, Emily Dumas, et al.Expert Review of Clinical Pharmacology|December 22, 2016
Update and trends on pharmacokinetic studies in patients with impaired renal function: practical insight into application of the FDA and EMA guidelinesSabina Paglialunga, Elliot Offman, Nita Ichhpurani, et al.Kidney International Reports|March 18, 2021
NaPi-IIb Inhibition for Hyperphosphatemia in CKD Hemodialysis PatientsSonomi Maruyama, Thomas C Marbury, Jeffrey Connaire, et al.Pageof 8